Wave Life Sciences (NASDAQ:WVE) Earning Somewhat Favorable Press Coverage, Study Finds

News headlines about Wave Life Sciences (NASDAQ:WVE) have been trending somewhat positive on Thursday, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Wave Life Sciences earned a news impact score of 0.07 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.4772812156309 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Shares of NASDAQ WVE traded up $1.55 during trading on Thursday, reaching $40.10. 143,467 shares of the stock traded hands, compared to its average volume of 164,486. Wave Life Sciences has a 52-week low of $15.15 and a 52-week high of $55.95. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.67 and a quick ratio of 7.67. The stock has a market capitalization of $1,112.69, a PE ratio of -10.44 and a beta of 0.14.

Several equities analysts have issued reports on the company. Leerink Swann dropped their price target on Wave Life Sciences from $64.00 to $62.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 13th. Mizuho set a $34.00 price objective on Wave Life Sciences and gave the company a “buy” rating in a report on Tuesday, February 20th. BidaskClub upgraded Wave Life Sciences from a “hold” rating to a “buy” rating in a report on Tuesday, February 13th. SunTrust Banks boosted their price objective on Wave Life Sciences to $60.00 and gave the stock a “buy” rating in a research report on Friday, March 9th. Finally, TheStreet raised Wave Life Sciences from a “d+” rating to a “c-” rating in a research report on Friday, January 5th. Two research analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $53.40.

In related news, insider Chandra Vargeese sold 2,000 shares of the stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $40.00, for a total transaction of $80,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Michael A. Panzara sold 511 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $52.10, for a total value of $26,623.10. The disclosure for this sale can be found here. Insiders have sold a total of 24,466 shares of company stock worth $1,321,808 in the last ninety days. Insiders own 53.00% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Wave Life Sciences (NASDAQ:WVE) Earning Somewhat Favorable Press Coverage, Study Finds” was originally posted by BBNS and is the property of of BBNS. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://baseballnewssource.com/2018/03/29/wave-life-sciences-wve-given-daily-news-impact-score-of-0-07/1972928.html.

Wave Life Sciences Company Profile

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Insider Buying and Selling by Quarter for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings


Leave a Reply

 
© 2006-2018 BBNS.